Literature DB >> 19962962

Laminarin-mediated targeting to Dectin-1 enhances antigen-specific immune responses.

Jianhui Xie1, Liang Guo, Yuanyuan Ruan, Haiyan Zhu, Lan Wang, Lei Zhou, Xiaojing Yun, Jianxin Gu.   

Abstract

It has immense potential for immunotherapy and vaccination to target antigens to antigen-presenting cells (APCs). Here we described a method for delivering whole protein antigens to APCs via carbohydrate-mediated targeting of Dectin-1, which is a C-type lectin and mainly expresses on subpopulations of dendritic cells and macrophages. Laminarin, which is a beta-1-3 glucan and a typical ligand for Dectin-1, was chemically coupled to ovalbumin (OVA). Compared to OVA alone, the conjugate was effectively recognized and ingested by CHO cells stably expressing Dectin-1 and bound to bone marrow dendritic cells (BMDCs) via Dectin-1. Laminarin modification led to significant enhancement of OVA-specific CD4(+) T-cell response. Moreover, when used to immunize mice, the conjugate enhanced the primary IgG antibody response to OVA. Taken together, our data suggest that APCs targeting based on glucan-Dectin-1 interaction is a promising approach to improve vaccines. Copyright 2009 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19962962     DOI: 10.1016/j.bbrc.2009.11.173

Source DB:  PubMed          Journal:  Biochem Biophys Res Commun        ISSN: 0006-291X            Impact factor:   3.575


  13 in total

Review 1.  Therapeutic targeting of trained immunity.

Authors:  Willem J M Mulder; Jordi Ochando; Leo A B Joosten; Zahi A Fayad; Mihai G Netea
Journal:  Nat Rev Drug Discov       Date:  2019-07       Impact factor: 84.694

2.  Immunoregulatory Activity of the Natural Product Laminarin Varies Widely as a Result of Its Physical Properties.

Authors:  Alyson J Smith; Bridget Graves; Robert Child; Peter J Rice; Zuchao Ma; Douglas W Lowman; Harry E Ensley; Kendal T Ryter; Jay T Evans; David L Williams
Journal:  J Immunol       Date:  2017-12-15       Impact factor: 5.422

3.  Characterization and optimization of the glucan particle-based vaccine platform.

Authors:  Haibin Huang; Gary R Ostroff; Chrono K Lee; Charles A Specht; Stuart M Levitz
Journal:  Clin Vaccine Immunol       Date:  2013-08-14

Review 4.  Advances in the Immunomodulatory Properties of Glycoantigens in Cancer.

Authors:  Valeria da Costa; Teresa Freire
Journal:  Cancers (Basel)       Date:  2022-04-07       Impact factor: 6.575

5.  Role of Dectin-1 in the innate immune response of rat corneal epithelial cells to Aspergillus fumigatus.

Authors:  Qiang Xu; Guiqiu Zhao; Jing Lin; Qian Wang; Liting Hu; Zhao Jiang
Journal:  BMC Ophthalmol       Date:  2015-10-01       Impact factor: 2.209

6.  Laminarin promotes anti-cancer immunity by the maturation of dendritic cells.

Authors:  Kyeongeun Song; Li Xu; Wei Zhang; Yun Cai; Bian Jang; Junghwan Oh; Jun-O Jin
Journal:  Oncotarget       Date:  2017-06-13

Review 7.  Phycochemical Constituents and Biological Activities of Fucus spp.

Authors:  Marcelo D Catarino; Artur M S Silva; Susana M Cardoso
Journal:  Mar Drugs       Date:  2018-07-27       Impact factor: 5.118

8.  Laminarin counteracts diet-induced obesity associated with glucagon-like peptide-1 secretion.

Authors:  Liusong Yang; Lina Wang; Canjun Zhu; Junguo Wu; Yexian Yuan; Lulu Yu; Yaqiong Xu; Jingren Xu; Tao Wang; Zhengrui Liao; Songbo Wang; Xiaotong Zhu; Ping Gao; Yongliang Zhang; Xiuqi Wang; Qingyan Jiang; Gang Shu
Journal:  Oncotarget       Date:  2017-08-03

Review 9.  Targeting C-type lectin receptors: a high-carbohydrate diet for dendritic cells to improve cancer vaccines.

Authors:  Dieke van Dinther; Dorian A Stolk; Rieneke van de Ven; Yvette van Kooyk; Tanja D de Gruijl; Joke M M den Haan
Journal:  J Leukoc Biol       Date:  2017-07-20       Impact factor: 4.962

10.  Prevention of Obesity Related Diseases through Laminarin-induced targeted delivery of Bindarit.

Authors:  Chunmei Xu; Luqi Yin; Zhipeng Teng; Xuemei Zhou; Wenjie Li; Qiong Lai; Cuiping Peng; Chengyuan Zhang; Jie Lou; Xing Zhou
Journal:  Theranostics       Date:  2020-07-25       Impact factor: 11.556

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.